Schroder Investment Management Group’s NovoCure NVCR Stock Holding History

Schroder Investment Management Group’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43M	Sell	415,340 -604,629	-59%	-$9.15M	﹤0.01%	743
2026 Q1	$10.6M	Hold	1,019,969	–	–	0.01%	647
2025 Q4	$13.5M	Buy	1,019,969 +575,222	+129%	+$7.38M	0.01%	591
2025 Q3	$5.75M	Buy	+444,747	New	+$5.94M	﹤0.01%	749
2025 Q1	–	Sell	-74,000	Closed	-$2.23M	–	1248
2024 Q4	$2.23M	Hold	74,000	–	–	﹤0.01%	910
2024 Q3	$1.16M	Hold	74,000	–	–	﹤0.01%	1013
2024 Q2	$1.27M	Hold	74,000	–	–	﹤0.01%	990
2024 Q1	$1.16M	Hold	74,000	–	–	﹤0.01%	1002
2023 Q4	$1.1M	Buy	+74,000	New	+$990K	﹤0.01%	1000
2022 Q2	–	Sell	-3,732	Closed	-$314K	–	1366
2022 Q1	$314K	Buy	3,732 +1,367	+58%	+$101K	﹤0.01%	1267
2021 Q4	$178K	Hold	2,365	–	–	﹤0.01%	1254
2021 Q3	$275K	Hold	2,365	–	–	﹤0.01%	1292
2021 Q2	$524K	Buy	2,365 +755	+47%	+$147K	﹤0.01%	1216
2021 Q1	$213K	Sell	1,610 -55,288	-97%	-$8.75M	﹤0.01%	1317
2020 Q4	$9.85M	Buy	+56,898	New	+$7.79M	0.01%	636

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Schroder Investment Management Group's NVCR Position: Q2 2026 in Review

Schroder Investment Management Group reduced its NovoCure (NVCR) stake by 59% in Q2 2026, selling an estimated $9.15M and leaving 415,340 shares worth $6.43M. The position accounts for ﹤0.01% of the portfolio, ranked #743.

Schroder Investment Management Group first reported a position in NVCR in Q4 2020 and has held it in 15 quarters since. The position peaked at $13.5M in Q4 2025. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Schroder Investment Management Group held 415,340 shares of NovoCure worth $6.43M as of Q2 2026.
Schroder Investment Management Group sold 604,629 NovoCure shares in Q2 2026, an estimated $9.15M.
NovoCure made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #743 holding.
Schroder Investment Management Group first reported a position in NovoCure in Q4 2020 and has held it in 15 quarters since.
Schroder Investment Management Group's NovoCure position peaked at $13.5M in Q4 2025.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.